Alvotech Reports Q1 2026 Earnings with Revenue Decline and Adjusted EBITDA Growth
Alvotech (ALVO) reported first-quarter earnings for fiscal year 2026, showing a revenue decline of $106 million due to timing of milestones and manufacturing slowdowns. However, adjusted EBITDA rose to $24 million with an improved margin of 23%. The company also noted progress in product launches including AVT02 (Humira biosimilar) and AVT04 (Stelara biosimilar), while maintaining a cash balance of $64 million.
Topics: ebitda gross_margin licensing_revenues product_revenues revenue